When private-equity veteran Craig Boyce left nearly two decades at Bain Capital and neuroscientist Dr. Melanie Leitner stepped out of the lab, both carried a deeply personal mission: speed up the end of ALS. Together they helm the ALS Investment Fund, a for-profit venture vehicle that backs early-stage therapeutics aimed at turning the disease from terminal to chronically managed by filling the “capital void” between basic research and big-pharma buy-in.
In this conversation with Tim and Troy, Craig recounts losing his father to ALS and how that tragedy redirected his deal-making skills toward impact investing, while Melanie shares the “seventh-grade brain report” that launched her career and why today’s biomarker and platform-trial advances finally make true progress possible. They break down:
If you’re curious how finance, science, and relentless human stories converge to accelerate cures, this episode delivers a front-row seat.
SPONSORS:
ElevenLabs: Thanks to ElevenLabs (https://elevenlabs.io) for supporting this episode and powering Tim’s voice.
ALS Investment Fund: Thanks to ALS Investment Fund (https://www.alsinvestmentfund.com) for supporting this episode.
SOCIAL:
Website: https://tgnlu.com
Twitter: https://twitter.com/nlutimgreen
Facebook: https://www.facebook.com/NLUpod
Instagram: https://www.instagram.com/nlupod/
AUDIO ONLY:
Spotify: https://open.spotify.com/show/5fhcANt7CSnYvgBlgxpVVa
Apple Podcasts: https://podcasts.apple.com/us/podcast/nothing-left-unsaid/id1734094890
PERSONAL:
Tackle ALS: https://www.tackleals.com
Tim Green Books: https://authortimgreen.com
Learn more about your ad choices. Visit megaphone.fm/adchoices